Another interesting CAR T therapy target is CD37, a transmembrane molecule whose expression is restricted to mature B cells that has been found specifically expressed in non-Hodgkin B cell lymphomas, CLL and some cases of cutaneous and peripheral T cell lymphomas. Here, CD37 is linked to B-cell chronic lymphocytic leukemia.